TGF-β Signaling via TAK1 Pathway: Role in Kidney Fibrosis

Seminars in Nephrology

Volumn 32, Issue 3, 2012, Pages 244-252

  Choi, Mary E ^a   Ding, Yan ^a   Kim, Sung Il ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic kidney disease; Fibrosis; Intracellular signaling; TGF activated kinase 1; Transforming growth factor 1

Indexed keywords

AUTOPHAGY PROTEIN 5; BECLIN 1; DEATH ASSOCIATED PROTEIN KINASE; FRESOLIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PIRFENIDONE; PLACEBO; SMAD6 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN PROTEIN LIGASE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; DRUG TARGETING; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; HUMAN; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; MESANGIUM CELL; MOLECULAR MECHANICS; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

FIBROSIS; HUMANS; KIDNEY; MAP KINASE KINASE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84864120935     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.04.003     Document Type: Article

References (103)

1. Levey A.S., Atkins R., Coresh J., Cohen E.P., Collins A.J., Eckardt K.U., et al. Chronic kidney disease as a global public health problem: approaches and initiatives-a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007, 72:247-259.
2. Iwano M., Neilson E.G. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens 2004, 13:279-284.
3. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007, 117:524-529.
4. Boor P., Ostendorf T., Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010, 6:643-656.
5. Klahr S., Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002, 283:F861-F875.
6. Border W.A., Noble N.A. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
7. Cheng J., Grande J.P. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med 2002, 227:943-956.
8. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
9. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 1998, 67:753-791.
10. Lee L.K., Meyer T.W., Pollock A.S., Lovett D.H. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 1995, 96:953-964.
11. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor β in human disease. N Engl J Med 2000, 342:1350-1358.
12. Majesky M.W., Volkhard L., Twardzik D.R., Schwartz S.M., Reidy M.A. Production of transforming growth factor β1 during repair of arterial injury. J Clin Invest 1991, 88:904-910.
13. Singer A.J., Clark R.A.F. Cutaneous wound healing. N Engl J Med 1999, 341:738-746.
14. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
15. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., et al. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993, 90:770-774.
16. Wang W., Huang X.R., Li A.G., Liu F., Truong L.D., Wang X.J., et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 2005, 16:1371-1383.
17. Massagué J. How cells read TGF-β signals. Nature Rev 2000, 1:169-178.
18. Massagué J., Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J 2000, 19:1745-1754.
19. Wu G., Chen Y.G., Ozdamar B., Gyuricza C.A., Chong P.A., Wrana J.L., et al. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 2000, 287:92-97.
20. Chen Y.G., Hata A., Lo R.S., Wotton D., Shi Y., Pavletich N., et al. Determinants of specificity in TGF-beta signal transduction. Genes Dev 1998, 12:2144-2152.
21. Massagué J., Seoane J., Wotton D. Smad transcription factors. Genes Dev 2005, 19:2783-2810.
22. Shi Y., Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
23. Massagué J., Blain S.W., Lo R.S. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
24. Bottinger E.P., Bitzer M. TGF-β signaling in renal disease. J Am Soc Nephrol 2002, 13:2600-2610.
25. Schnaper H.W., Hayashida T., Poncelet A.C. It's a Smad world: regulation of TGF-β signaling in the kidney. J Am Soc Nephrol 2001, 13:1126-1128.
26. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
27. Moustakas A., Heldin C.H. Non-Smad TGF-beta signals. J Cell Sci 2005, 118:3573-3584.
28. Edlund S., Landström M., Heldin C.H., Aspenström P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002, 13:902-914.
29. Bhowmick N.A., Ghiassi M., Bakin A., Aakre M., Lundquist C.A., Engel M.E., et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001, 12:27-36.
30. Bakin A.V., Tomlinson A.K., Bhowmick N.A., Moses H.L., Arteaga C.L. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000, 275:36803-36810.
31. Yi J.Y., Shin I., Arteaga C.L. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem 2005, 280:10870-10876.
32. Wilkes M.C., Mitchell H., Penheiter S.G., Doré J.J., Suzuki K., Edens M., et al. Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 2005, 65:10431-10440.
33. Ding Y., Kim J.K., Kim S.I., Na H.J., Jun S.Y., Lee S.J., et al. TGF-beta1 protects against mesangial cell apoptosis via induction of autophagy. J Biol Chem 2010, 285:37909-37919.
34. Hartsough M.T., Mulder K.M. Transforming growth factor β activation of p44mapk in proliferating cultures of epithelial cells. J Biol Chem 1995, 270:7117-7124.
35. Mucsi I., Skorecki K.L., Goldberg H.J. Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-beta1 on gene expression. J Biol Chem 1996, 271:16567-16572.
36. Atfi A., Djelloul S., Chastre E., Davis R., Gespach C. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem 1997, 272:1429-1432.
37. Hocevar B.A., Brown T.L., Howe P.H. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999, 18:1345-1356.
38. Yue J., Sun B., Liu G., Mulder K.M. Requirement of TGF-beta receptor-dependent activation of c-Jun N-terminal kinases (JNKs)/stress-activated protein kinases (Sapks) for TGF-beta up-regulation of the urokinase-type plasminogen activator receptor. J Cell Physiol 2004, 199:284-292.
39. Hanafusa H., Ninomiya-Tsuji J., Masuyama N., Nishita M., Fujisawa J., Shibuya H., et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 1999, 274:27161-27167.
40. Chin B.Y., Mohsenin A., Li S.X., Choi A.M., Choi M.E. Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway. Am J Physiol Renal Physiol 2001, 280:F495-F504.
41. Wang L., Ma R., Flavell R.A., Choi M.E. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for activation of p38alpha and p38delta MAPK isoforms by TGF-beta 1 in murine mesangial cells. J Biol Chem 2002, 277:47257-47262.
42. Rodriguez-Barbero A., Obreo J., Yuste L., Montero J.C., Rodriguez-Pena A., Pandiella A., et al. Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. FEBS Lett 2002, 513:282-288.
43. Lim A.K., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Thomas M.C., Flavell R.A., et al. Role of MKK3-p38 MAPK signaling in the development of type 2 diabetes and renal injury in obese db/db mice. Diabetologia 2009, 52:347-358.
44. Stambe C., Atkins R.C., Tesch G.H., Masaki T., Schreiner G.F., Nikolic-Paterson D.J. The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol 2004, 15:370-379.
45. Adhikary L., Chow F., Nikolic-Paterson D.J., Stambe C., Dowling J., Atkins R.C., et al. Abnormal p38 mitogen-activated protein kinase signaling in human and experimental diabetic nephropathy. Diabetologia 2004, 47:1210-1222.
46. Ono K., Ohtomo T., Ninomiya-Tsuji J., Tsuchiya M. A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-β. Biochem Biophys Res Commun 2003, 307:332-337.
47. Kim S.I., Kwak J.H., Zachariah M., He Y., Wang L., Choi M.E. TGF-beta-activated kinase 1 and TAK1-binding protein 1 cooperate to mediate TGF-beta1-induced MKK3-p38 MAPK activation and stimulation of type I collagen. Am J Physiol Renal Physiol 2007, 292:F1471-F1478.
48. Hocevar B.A., Prunier C., Howe P.H. Disabled-2 (Dab2) mediates transforming growth factor β (TGFβ)-stimulated fibronectin synthesis through TGFβ-activated kinase 1 and activation of the JNK pathway. J Biol Chem 2005, 280:25920-25927.
49. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270:2008-2011.
50. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996, 272:1179-1182.
51. Shirakabe K., Yamaguchi K., Shibuya H., Irie K., Matsuda S., Moriguchi T., et al. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J Biol Chem 1997, 272:8141-8144.
52. Sakurai H., Suzuki S., Kawasaki N., Nakano H., Okazaki T., Chino A., et al. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 2003, 278:36916-36923.
53. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999, 398:252-256.
54. Irie T., Muta T., Takeshig K. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-kappaB in lipopolysaccharide-stimulated macrophages. FEBS Lett 2000, 467:160-164.
55. Kishimoto K., Matsumoto K., Ninomiya-Tsuji J. TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J Biol Chem 2000, 275:7359-7364.
56. Singhirunnusorn P., Suzuki S., Kawasaki N., Saiki I., Sakurai H. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem 2005, 280:7359-7368.
57. Xie M., Zhang D., Dyck J.R., Li Y., Zhang H., Morishima M., et al. A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A 2006, 103:17378-17383.
58. Smit L., Baas A., Kuipers J., Korswagen H., van de Wetering M., Clevers H. Wnt activates the Tak1/Nemo-like kinase pathway. J Biol Chem 2004, 279:17232-17240.
59. Dowdy S.C., Mariani A., Janknecht R. HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem 2003, 278:44377-44384.
60. Hoffmann A., Preobrazhenska O., Wodarczyk C., Medler Y., Winkel A., Shahab S., et al. Transforming growth factor-beta-activated kinase-1 (TAK1), a MAP3K, interacts with Smad proteins and interferes with osteogenesis in murine mesenchymal progenitors. J Biol Chem 2005, 280:27271-27283.
61. Sano Y., Harada J., Tashiro S., Gotoh-Mandeville R., Maekawa T., Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem 1999, 274:8949-8957.
62. Abécassis L., Rogier E., Vazquez A., Atfi A., Bourgeade M.F. Evidence for a role of MSK1 in transforming growth factor-beta-mediated responses through p38alpha and Smad signaling pathways. J Biol Chem 2004, 279:30474-30479.
63. Sakurai H., Miyoshi H., Mizukami J., Sugita T. Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett 2000, 474:141-145.
64. Ishitani T., Takaesu G., Ninomiya-Tsuji J., Shibuya H., Gaynor R.B., Matsumoto K. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J 2003, 22:6277-6288.
65. Cheung P.C., Nebreda A.R., Cohen P. TAB3, a new binding partner of the protein kinase TAK1. Biochem J 2004, 378:27-34.
66. Inagaki M., Omori E., Kim J.Y., Komatsu Y., Scott G., Ray M.K., et al. TAK1-binding protein 1, TAB1, mediates osmotic stress-induced TAK1 activation but is dispensable for TAK1-mediated cytokine signaling. J Biol Chem 2008, 283:33080-33086.
67. Komatsu Y., Shibuya H., Takeda N., Ninomiya-Tsuji J., Yasui T., Miyado K., et al. Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis. Mech Dev 2002, 119:239-249.
68. Kim S.I., Kwak J.H., Na H.J., Kim J.K., Ding Y., Choi M.E. Transforming growth factor-beta (TGF-β1) activated TAK1 via TAB1-mediated autophosphorylation, independent of TGF-beta receptor kinase activity in mesangial cells. J Biol Chem 2009, 284:22285-22296.
69. Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V., Schuster N., et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008, 10:1199-1207.
70. Yamashita M., Fatyol K., Jin C., Wang X., Liu Z., Zhang Y.E. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β. Mol Cell 2008, 31:918-924.
71. Kanayama A., Seth R.B., Sun L., Ea C.K., Hong M., Shaito A., et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 2004, 15:535-548.
72. Mu Y., Sundar R., Thakur N., Ekman M., Gudey S.K., Yakymovych M., et al. TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer. Nat Commun 2011, 2:330.
73. Hanada M., Ninomiya-Tsuji J., Komaki K., Ohnishi M., Katsura K., Kanamaru R., et al. Regulation of the TAK1 signaling pathway by protein phosphatase 2C. J Biol Chem 2001, 276:5753-5759.
74. Li M.G., Katsura K., Nomiyama H., Komaki K., Ninomiya-Tsuji J., Matsumoto K., et al. Regulation of the interleukin-1-induced signaling pathways by a novel member of the protein phosphatase 2C family (PP2Cepsilon). J Biol Chem 2003, 278:12013-12021.
75. Kajino T., Ren H., Iemura S., Natsume T., Stefansson B., Brautigan D.L., et al. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J Biol Chem 2006, 281:39891-39896.
76. Broglie P., Matsumoto K., Akira S., Brautigan D.L., Ninomiya-Tsuji J. Transforming growth factor beta-activated kinase 1 (TAK1) kinase adaptor, TAK1-binding protein 2, plays dual roles in TAK1 signaling by recruiting both an activator and an inhibitor of TAK1 kinase in tumor necrosis factor signaling pathway. J Biol Chem 2010, 285:2333-2339.
77. Kim S.I., Kwak J.H., Wang L., Choi M.E. Protein phosphatase 2A is a negative regulator of transforming growth factor-beta1-induced TAK1 activation in mesangial cells. J Biol Chem 2008, 283:10753-10763.
78. Zhang D., Gaussin V., Taffet G.E., Belaguli N.S., Yamada M., Schwartz R.J., et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 2000, 6:556-563.
79. Shi-wen X., Parapuram S.K., Pala D., Chen Y., Carter D.E., Eastwood M., et al. Requirement of transforming growth factor β-activated kinase 1 for transforming growth factor β-induced alpha-smooth muscle actin expression and extracellular matrix contraction in fibroblasts. Arthritis Rheum 2009, 60:234-241.
80. Ma F.Y., Tesch G.H., Flavell R.A., Davis R.J., Nikolic-Paterson D.J. MKK3-p38 signaling promotes apoptosis and the early inflammatory response in the obstructed mouse kidney. Am J Physiol Renal Physiol 2007, 293:F1556-F1563.
81. Tan H.B., Feng Y., Liu M., Wu Y.C. Protective effects of FR167653 on chronic allograft nephropathy by inhibiting p38 MAPK in rats. Transplant Proc 2008, 40:1685-1689.
82. Flanc R.S., Ma F.Y., Tesch G.H., Han Y., Atkins R.C., Bennett B.L., et al. A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int 2007, 72:698-708.
83. de Borst M.H., Prakash J., Sandovici M., Klok P.A., Hamming I., Kok R.J., et al. c-Jun NH2-terminal kinase is crucially involved in renal tubulo-interstitial inflammation. J Pharmacol Exp Ther 2009, 331:896-905.
84. Kanellis J., Ma F.Y., Kandane-Rathnayake R., Dowling J.P., Polking-Horne K.R., Bennett B.L., et al. JNK signaling in human and experimental renal ischaemia/reperfusion injury. Nephrol Dial Transplant 2010, 25:2898-2908.
85. Ma F.Y., Flanc R.S., Tesch G.H., Han Y., Atkins R.C., Bennett B.L., et al. A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol 2007, 18:472-484.
86. Sakai N., Wada T., Furuichi K., Iwata Y., Yoshimoto K., Kitagawa K., et al. p38 MAPK phosphorylation and NF-kappa B activation in human crescentic glomerulonephritis. Nephrol Dial Transplant 2002, 17:998-1004.
87. Stambe C., Nikolic-Paterson D.J., Hill P.A., Dowling J., Atkins R.C. p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J Am Soc Nephrol 2004, 15:326-336.
88. Ma F.Y., Tesch G.H., Ozols E., Xie M., Schneider M.D., Nikolic-Paterson D.J. TGF-β1 activated kinase-1 (TAK1) regulates inflammation and fibrosis in the obstructed kidney. Am J Physiol Renal Physiol 2011, 300:F1410-F1421.
89. Inokuchi S., Aoyama T., Miura K., Osterreicher C.H., Kodama Y., Miyai K., et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A 2010, 107:844-849.
90. Omori E., Matsumoto K., Zhu S., Smart R.C., Ninomiya-Tsuji J. Ablation of TAK1 upregulates reactive oxygen species and selectively kills tumor cells. Cancer Res 2010, 70:8417-8425.
91. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004, 6:463-477.
92. Kiyono K., Suzuki H.I., Matsuyama H., Morishita Y., Komuro A., Kano M.R., et al. Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. Cancer Res 2009, 69:8844-8852.
93. Tanida I., Ueno T., Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2004, 36:2503-2518.
94. He C., Klionsky D.J. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 2009, 43:67-93.
95. Li D.D., Wang L.L., Deng R., Tang J., Shen Y., Guo J.F., et al. The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene 2009, 28:886-898.
96. Wei Y., Pattingre S., Sinha S., Bassik M., Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008, 30:678-688.
97. Herrero-Martin G., Hoyer-Hansen M., Garcia-Garcia C., Fumarola C., Farkas T., Lopez-Rivas A., et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J 2009, 28:677-685.
98. Hou W., Han J., Lu C., Goldstein L.A., Rabinowich H. Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis. Autophagy 2010, 6:891-900.
99. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007, 56:L323-L333.
100. Trachtman H., Fervenza F.C., Gipson D.S., Heering P., Jayne D.R., Peters H., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011, 79:1236-1243.
101. RamachandraRao S.P., Zhu Y., Ravasi T., McGowan T.A., Toh I., Dunn S.R., et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009, 20:1765-1775.
102. Taniguchi H., Ebina M., Kondoh Y., Ogura T., Azuma A., Suga M., et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.
103. Cho M.E., Smith D.C., Branton M.H., Penzak S.R., Kopp J.B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007, 2:906-913.